Metastases, Neoplasm Clinical Trial
Official title:
Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metastases
The investigators hypothesize that with dose escalation to 40-50 Gy in ten fractions, the complete pain response rate at one month can be increased to 40-50% in painful non-spinal bone metastases. Additionally, the investigators hypothesize that utilizing a fractionation scheme with an escalated biologically equivalent dose (BED) will result in a higher proportion of participants responding to treatment, and will also lead to more durable responses. Furthermore, the investigators hypothesize that with dose escalation to 40-50 Gy in ten fractions, the complete pain response rate at one month can be increased to 35-45% in painful non-bone metastases
The purpose of this study is to prospectively evaluate dose escalation and pain response in patients with painful non-spinal bone metastases and painful non-bone metastases treated with radiation therapy. Primary Objective: To evaluate improvement of complete pain response rate in painful non-spine bone metastases and painful non-bone metastases with dose escalated radiation using a ten fraction radiation regimen Secondary Objectives: To evaluate best pain response To evaluate mean pain scores To evaluate the duration of pain response To evaluate the changes in quality-of-life following radiation To evaluate the rates of retreatment with radiation secondary to disease or symptom progression To evaluate treatment related toxicity ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00065117 -
Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer.
|
Phase 2 | |
| Completed |
NCT00039780 -
Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel
|
Phase 3 | |
| Terminated |
NCT00048893 -
Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT00037869 -
High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors
|
Phase 3 | |
| Completed |
NCT02265549 -
Radiomics for Prediction of Long Term Survival and Local Failure After Stereotactic Radiotherapy for Brain Metastases
|
N/A | |
| Completed |
NCT00034918 -
This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Metastatic Breast Cancer
|
Phase 2 | |
| Completed |
NCT01115751 -
A Study in Patients With Advanced or Metastatic Cancer
|
Phase 1 | |
| Terminated |
NCT01115803 -
A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
|
Phase 1 | |
| Completed |
NCT00056173 -
Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma
|
Phase 1/Phase 2 | |
| Terminated |
NCT00034697 -
Study of Temozolomide in the Treatment of Brain Metastasis From Non-small-cell Lung Cancer (Study P02143)
|
Phase 2 | |
| Completed |
NCT00055471 -
A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer
|
Phase 2 | |
| Completed |
NCT00046527 -
Study of ABI-007 and Taxol in Patients With Metastatic Breast Cancer
|
Phase 3 | |
| Completed |
NCT00046514 -
ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Completed |
NCT00041808 -
Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver
|
Phase 1/Phase 2 | |
| Completed |
NCT00037609 -
Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT00038038 -
Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole
|
N/A | |
| Completed |
NCT03670992 -
Surgical Treatment of Pancreatic RCC Metastases
|
||
| Terminated |
NCT00050336 -
Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)(TERMINATED)
|
Phase 3 | |
| Recruiting |
NCT03563326 -
Intraperitoneal Infusion of EpCAM CAR-T Cell in Advanced Gastric Cancer With Peritoneal Metastasis (WCH-GC-CART)
|
Phase 1 | |
| Completed |
NCT00044863 -
Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma
|
Phase 2 |